Reelin protein rescues cognitive deficits in an animal model of Alzheimer's disease

March 7, 2014, University of Barcelona
From left to right, Daniela Rossi, Lluís Pujadas, Eduardo Soriano and Natàlia Carulla.

Reelin, a crucial protein for adult brain plasticity, recovers cognitive functions in mice with Alzheimer's disease. This is one of the main results of an article published on the journal Nature Communications, co-led by Eduardo Soriano, professor from the Department of Cell Biology at the University of Barcelona (UB) and member of the Centre for Networked Biomedical Research on Neurodegenerative Diseases (CIBERNED), and researcher Lluís Pujadas (UB and CIBERNED).

The study is part of the PhD thesis developed by Daniela Rossi, co-author of the article together with Lluís Pujadas. Natàlia Carulla, from the Institute for Research in Biomedicine (IRB), collaborated actively in the research too. Other participants are: M. Rosa Andrés, Cátia M. Teixeira, Antoni Parcerisas, Ernest Giralt, Bernat Serra and Rafael Maldonado, and the institutions Research Center for Neurological Diseases Foundation (CIEN Foundation), Vall d'Hebron Research Institute (VHIR) and Pompeu Fabra University (UPF).

To recover cognitive functions in models of Alzheimer's disease

Alzheimer's disease is a neurodegenerative disease characterised by progressive cognitive deficits, synaptic loss and neuronal death. It is mainly associated with the formation of senile plaques (extracellular deposits of amyloid-β, Aβ) and the presence of neurofibrillary tangles (intracellular bundles of tau protein). The disease, which is the most common form of dementia in the elderly, affects more than 100,000 people in Catalonia and 500,000 in Spain, and causes progressive degeneration of patients' intellectual and cognitive functions.

This new preclinical study proves that an increase in Reelin brain levels avoids cognitive deterioration in mouse models of Alzheimer's disease. Moreover, Reelin delays amyloid-beta fibril formation in vitro and reduces amyloid deposits in mice with Alzheimer's.

The double pathway of Aβ peptide and tau protein

Professor Eduardo Soriano, head of the Research Group Developmental Neurobiology and Neuroregeneration of UB, explains that "most studies on Alzheimer's disease search for therapeutic targets addressed to a certain process involved in the disease." On the contrary, "our study analyses the signalling pathway of Reelin—a synaptic and cognitive enhancer— that regulates the (APP) and tau protein, which are both involved in basic processes of Alzheimer's disease."

Lluís Pujadas, first author of the article together with Daniela Rossi, points out: "We knew that Reelin is involved in the double regulating pathway of Aβ peptide and , but it was difficult to understand their interaction."

"The study shows a new mechanism that enables to understand better the link between both aspects of the disease," he adds. The investigation describes how Reelin, trapped into amyloid fibrils, loses its ability to promote plasticity; thus, Reelin overexpression may be beneficial.

The most toxic peptides in Alzheimer's disease

Experts also describe how Reelin interacts in vitro and reduces the toxicity of Aβ42 peptide, responsible for fibril formation and the aggregation of senile plaques. Reelin interaction with Aβ42 peptides —nowadays considered the most toxic— was not described to date. It is the first time that a study proves that the presence of Reelin reduces Aβ42 peptides toxicity," affirms Daniela Rossi, from the Department of Cell Biology of UB.

In vitro results show that Reelin interacts with Aβ42 peptide and delays fibril formation. Results were reproduced in a mouse model of Alzheimer's disease and it was observed that Reelin also reduces amyloid plaque formation. The study demonstrates for the first time that Reelin has a neuroprotective effect in neurodegenerative diseases, proved in vivo in animal models, and provides a hypothesis to explain its neuroprotective potential.

Reelin: neuroprotective tool and cognitive enhancer

"The most striking result is that a brain plasticity promoter can rescue an Alzheimer's clinical phenotype in an animal model," says Eduardo Soriano. Cognitive deficits recovery takes place after the activation of a signalling pathway —Reelin signalling— which homeostatically regulates global neuronal function: cognition, neuronal plasticity, amyloid formation, etc. Soriano stresses that, as a research line, "this methodological approach on signalling pathways that control different features related to and Alzheimer's disease is more effective."

Alzheimer's disease causes remain unknown; only 1.5% of cases are congenital. In previous studies, the research group led by Dr Eduardo Soriano observed that Reelin was altered in Alzheimer's disease and that its role in intracellular signalling pathways was associated with neuronal survival. They also studied Reelin's role in different aspects related to adult brain physiological behaviour and the homeostatical potential of the protein. The article published in Nature Communications extends the search for therapeutic targets against Alzheimer's disease, and Reelin pathway deserves consideration as a therapeutic target for the treatment of Alzheimer's disease pathogenesis. In fact, researchers plan to have a system to identify chemical compounds that promote Reelin signalling in some months.

Explore further: New Alzheimer's research suggests possible cause: The interaction of proteins in the brain

More information: "Reelin delays amyloid-beta fibril formation and rescues cognitive deficits in a model of Alzheimer's disease." Lluís Pujadas, Daniela Rossi, Rosa Andrés,Cátia M. Teixeira, Bernat Serra-Vidal, Antoni Parcerisas, Rafael Maldonado, Ernest Giralt, Natàlia Carulla & Eduardo Soriano. Nature Communications. Volume: 5, Article number:3443 DOI: 10.1038/ncomms4443

Related Stories

New Alzheimer's research suggests possible cause: The interaction of proteins in the brain

June 19, 2013
For years, Alzheimer's researchers have focused on two proteins that accumulate in the brains of people with Alzheimer's and may contribute to the disease: plaques made up of the protein amyloid-beta, and tangles of another ...

Fluorescent compounds allow clinicians to visualize Alzheimer's disease as it progresses

September 18, 2013
What if doctors could visualize all of the processes that take place in the brain during the development and progression of Alzheimer's disease? Such a window would provide a powerful aid for diagnosing the condition, monitoring ...

Alzheimer's in a dish: Stem cells from patients offer model and drug-discovery platform for early-onset form of disease

March 4, 2014
Harvard stem cell scientists have successfully converted skins cells from patients with early-onset Alzheimer's into the types of neurons that are affected by the disease, making it possible for the first time to study this ...

Key cellular auto-cleaning mechanism mediates the formation of plaques in Alzheimer's brain

October 3, 2013
Autophagy, a key cellular auto-cleaning mechanism, mediates the formation of amyloid beta plaques, one of the hallmarks of Alzheimer's disease. It might be a potential drug target for the treatment of the disease, concludes ...

Researchers discover an epigenetic lesion in the hippocampus of Alzheimer's

January 21, 2014
Alzheimer's disease can reach epidemic range in the coming decades, by the increasing average age of society. There are two key issues for Alzheimer's disease: there is currently no effective treatment and it has been described ...

Impaired recovery from inflammation linked to Alzheimer's disease

February 14, 2014
(Medical Xpress)—New research from Karolinska Institutet shows that the final stage of the normal inflammatory process may be disrupted in patients with Alzheimer's disease. A study published in the journal Alzheimer's ...

Recommended for you

Anxiety: An early indicator of Alzheimer's disease?

January 12, 2018
A new study suggests an association between elevated amyloid beta levels and the worsening of anxiety symptoms. The findings support the hypothesis that neuropsychiatric symptoms could represent the early manifestation of ...

One of the most promising drugs for Alzheimer's disease fails in clinical trials

January 11, 2018
To the roughly 400 clinical trials that have tested some experimental treatment for Alzheimer's disease and come up short, we can now add three more.

Different disease types associated with distinct amyloid-beta prion strains found in Alzheimer's patients

January 9, 2018
An international team of researchers has found different disease type associations with distinct amyloid-beta prion strains in the brains of dead Alzheimer's patients. In their paper published in Proceedings of the National ...

Advances in brain imaging settle debate over spread of key protein in Alzheimer's

January 5, 2018
Recent advances in brain imaging have enabled scientists to show for the first time that a key protein which causes nerve cell death spreads throughout the brain in Alzheimer's disease - and hence that blocking its spread ...

Molecular mechanism behind HIV-associated dementia revealed

January 5, 2018
For the first time, scientists have identified and inhibited a molecular process that can lead to neurodegeneration in patients with HIV, according to a Northwestern Medicine study published in Nature Communications.

Mice with frequent flier miles advance the Alzheimer's cause

January 4, 2018
Alzheimer's disease wreaks emotional havoc on patients, who are robbed of their memories, their dignity, and their lives. It's financially devastating as well: care for Alzheimer's patients is predicted to top $1 trillion ...


Adjust slider to filter visible comments by rank

Display comments: newest first

5 / 5 (1) Mar 07, 2014
Alzheimer's in mice is induced by known introduced brain defects. Consequently, treatment that reverses these introduced defects may "cure" Alzheimer's in these animals. The defects causing Alzheimer's in humans are very poorly known. This has made the development of new treatments difficult.

The author needs to tell what defects were introduced in the mice that were then treated with reelin. That will greatly help in assessing this work.
not rated yet Mar 09, 2014
Curcumin nanoparticles have been used to same purpose:

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.